帕金森抑郁症中受损的奖励敏感性对多巴胺治疗无反应
Harry Costello1,2, Yumeya Yamamori1, Karel Kieslich1
1Institute of Cognitive Neuroscience, University College London, London, WC1N 3AZ, UK.
Brain : a journal of neurology
|March 19, 2025
概括
帕金森病 (PD) 中的抑郁症涉及基于努力的决策能力受损,特别是奖励敏感性降低. 多巴胺药物在患有抑郁症的PD患者中没有改善这种情况,这表明需要非多巴胺治疗.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 行为经济学是一种行为经济学.
背景情况:
- 抑郁症在帕金森病 (PD) 中很常见,具有像冷漠一样的动机缺陷.
- 这些症状与多巴胺系统功能障碍有关,多巴胺系统是PD中受影响的关键区域.
- 基于努力的决策,对动机至关重要,严重依赖多巴胺基系统.
研究的目的:
- 调查多巴胺依赖于基于努力的决策中的干扰是否有助于帕金森病中的抑郁症.
- 为了比较基于努力的决策在PD患者和没有抑郁症,和对照.
- 评估多巴胺类药物对患有抑郁症和没有抑郁症的PD患者基于努力的决策的影响.
主要方法:
- 一个基于努力的决策任务涉及金钱奖励和体力 (抓力) 进行管理.
- 参与者包括62名PD患者 (有/没有抑郁症,开/关药) 和29名健康对照.
- 用后勤混合效应建模和计算建模分析了数据.
主要成果:
- 与其他所有组相比,患有PD抑郁症的患者的接受率明显较低.
- 这种接受度降低是由PD抑郁症中奖励敏感度降低所驱动的.
- 多巴胺药物改善了非抑郁PD患者的奖励灵敏度,但不是那些患有抑郁症的人.
结论:
- 基于努力的决策受损,对多巴胺无反应,是帕金森病中抑郁症的关键特征.
- 降低奖励敏感性是PD抑郁症背后的一个关键机制.
- 这表明,非多巴胺类疗法可能是治疗帕金森病抑郁症的必要条件.
相关概念视频
Parkinson's Disease: Treatment
170
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
170
Parkinson's Disease: Overview
405
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
405
Antidepressant Drugs: MAOIs and Other Agents
174
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
174
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Attention-Deficit/Hyperactivity Disorder
34
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
34
Depression: Overview
205
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
205


